<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab5">
 <label>Table 5</label>
 <caption>
  <p>Select novel antibiotics in development [
   <xref ref-type="bibr" rid="CR23">23</xref>, 
   <xref ref-type="bibr" rid="CR31">31</xref>, 
   <xref ref-type="bibr" rid="CR34">34</xref>] Google Scholar search
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug class</th>
    <th>Names and notes</th>
    <th>Indications</th>
    <th>Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Defensins [
     <xref ref-type="bibr" rid="CR5">5</xref>]
    </td>
    <td>Brilacidin</td>
    <td>Broad-spectrum antibacterial activity</td>
    <td/>
   </tr>
   <tr>
    <td>Medicinal leech and other animal venom as source for antimicrobial peptides [
     <xref ref-type="bibr" rid="CR35">35</xref>, 
     <xref ref-type="bibr" rid="CR36">36</xref>]
    </td>
    <td>Several peptides are studied</td>
    <td/>
    <td>Interest based on ability of leech to store blood for a long time</td>
   </tr>
   <tr>
    <td>Extremophile bacteria as sources of antibiotics [
     <xref ref-type="bibr" rid="CR36">36</xref>, 
     <xref ref-type="bibr" rid="CR37">37</xref>]
    </td>
    <td/>
    <td/>
    <td>Fusaricidin B isolated from hot springâ€“derived bacteria is assigned a new application for tuberculosis treatment</td>
   </tr>
   <tr>
    <td>Fluoroketolides</td>
    <td>Solithromycin [
     <xref ref-type="bibr" rid="CR23">23</xref>]
    </td>
    <td>Activity against 
     <italic>N. gonorrhoeae</italic>, 
     <italic>C. trachomatis</italic>, 
     <italic>M. genitalium</italic>, and Gram-positive respiratory pathogens
    </td>
    <td/>
   </tr>
   <tr>
    <td>Spiropyrimidinetrione topoisomerase II inhibitor</td>
    <td>Zoliflodacin</td>
    <td>Activity against XDR 
     <italic>N. gonorrhoeae</italic> and C. trachomatis
    </td>
    <td/>
   </tr>
   <tr>
    <td>Triazaacenaphthylenes</td>
    <td>Gepotidacin</td>
    <td>Activity against MRSA, ESBL Enterobacteriaceae, and 
     <italic>N. gonorrhoeae</italic>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Cephalosporin/vancomycin heterodimer</td>
    <td>Cefilavancin</td>
    <td>Gram-positive pathogens</td>
    <td/>
   </tr>
   <tr>
    <td>Ethambutol</td>
    <td>SQ 109</td>
    <td>
     <italic>M. tuberculosis</italic>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Non-absorbable small molecule antibiotic</td>
    <td>Ridinilazole</td>
    <td>
     <italic>Clostridium difficile</italic> all strains
    </td>
    <td>Granted fast track status by FDA</td>
   </tr>
   <tr>
    <td>Polymixins [
     <xref ref-type="bibr" rid="CR38">38</xref>]
    </td>
    <td>NAB741, CB-182804</td>
    <td>Gram negatives</td>
    <td>Early stages</td>
   </tr>
   <tr>
    <td>Peptidomimetic</td>
    <td>Murepavadin [
     <xref ref-type="bibr" rid="CR28">28</xref>, 
     <xref ref-type="bibr" rid="CR39">39</xref>]
    </td>
    <td>
     <italic>P. aeruginosa</italic> infections
    </td>
    <td>Novel mechanism of action pseudomonas specific</td>
   </tr>
   <tr>
    <td>Carbapenems</td>
    <td>Tebipenem [
     <xref ref-type="bibr" rid="CR40">40</xref>]
    </td>
    <td>Broad spectrum</td>
    <td>First carbapenem with oral formulation available</td>
   </tr>
   <tr>
    <td>Fluoroquinolones</td>
    <td>Nemonoxacin; zabofloxacin</td>
    <td>Broad spectrum with anti MRSA activity</td>
    <td>Approved and used in several countries</td>
   </tr>
   <tr>
    <td>Boronic acids</td>
    <td>RPX7009 [
     <xref ref-type="bibr" rid="CR41">41</xref>]
    </td>
    <td/>
    <td>B-Lactamase inhibitors</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
